Skip to main content
Premium Trial:

Request an Annual Quote

BGI Bid to Acquire Complete Genomics Passes US Antitrust Hurdle; Tender Offer Extended Again

NEW YORK (GenomeWeb News) – BGI-Shenzhen and Complete Genomics said today that their proposed merger has cleared US antitrust review.

The companies said that they have received early termination of the Hart-Scott-Rodino waiting period from the Federal Trade Commission regarding BGI's $118 million bid for Complete.

The news comes one week after the Committee on Foreign Investment in the United States cleared the proposed acquisition.

BGI also said today that it has extended its tender offer for Complete's shares to midnight EST on Jan 11. The offer had originally been scheduled to expire on Dec. 31, 2012, and was later extended to expire at midnight today.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more